Baricitinib Therapy in COVID-19
NCT04358614 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2020-04-24
Summary
Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
Conditions
Interventions
- DRUG
-
Baricitinib 4 MG Oral Tablet
Baricitinib+antiviral therapy administration for 2 weeks
Sponsors & Collaborators
-
Fabrizio Cantini
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-16
- Primary Completion
- 2020-04-05
- Completion
- 2020-04-07
Countries
- Italy
Study Locations
More Related Trials
-
Covid-19 Breath Test
NCT04459962 ·Status: COMPLETED ·Phase: NA
-
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)
NCT04317092 ·Status: UNKNOWN ·Phase: PHASE2
-
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive
NCT04333589 ·Status: UNKNOWN ·Phase: NA
-
COVID Breath Test - Ancon
NCT04760639 ·Status: COMPLETED
-
Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study
NCT04508556 ·Status: COMPLETED
-
Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia
NCT04332913 ·Status: UNKNOWN
-
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients
NCT04346355 ·Status: TERMINATED ·Phase: PHASE2
-
Detection of COVID-19 Using Breath Analysis - Validation Study
NCT04602949 ·Status: COMPLETED ·Phase: NA
-
Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.
NCT05094674 ·Status: UNKNOWN ·Phase: NA
-
Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
NCT04331795 ·Status: COMPLETED ·Phase: PHASE2
-
Leflunomide in Mild COVID-19 Patients
NCT04361214 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
NCT04372186 ·Status: COMPLETED ·Phase: PHASE3
-
Tocilizumab in Covid-19 Penumonia in Buenos Aires City
NCT05057962 ·Status: COMPLETED
-
European Pathology Laboratories and COVID-19
NCT04476823 ·Status: COMPLETED
-
COVID-19 Novel Molecular Point of Care Diagnostics Evaluation
NCT06055218 ·Status: COMPLETED
-
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
NCT05686629 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
NCT04500132 ·Status: COMPLETED ·Phase: PHASE2
-
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
NCT04853927 ·Status: WITHDRAWN ·Phase: PHASE3
-
Sensitivity Evaluation of Serological Tests for Covid-19
NCT04678024 ·Status: UNKNOWN
-
An Observational Study of Patients With Coronavirus Disease 2019
NCT04331886 ·Status: COMPLETED
-
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
NCT00001477 ·Status: COMPLETED
-
Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19
NCT04924829 ·Status: UNKNOWN
-
Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
NCT04709172 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
NCT04453384 ·Status: COMPLETED ·Phase: PHASE2
-
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
NCT04275388 ·Status: UNKNOWN